You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

CLINICAL TRIALS PROFILE FOR AMONAFIDE


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Amonafide

Trial ID Title Status Sponsor Phase Summary
NCT00074100 ↗ Amonafide in Treating Women With Metastatic Breast Cancer That Has Progressed After Previous Chemotherapy Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy, such as amonafide, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of amonafide in treating women who have metastatic breast cancer that has progressed after previous chemotherapy.
NCT00074100 ↗ Amonafide in Treating Women With Metastatic Breast Cancer That Has Progressed After Previous Chemotherapy Completed Memorial Sloan Kettering Cancer Center Phase 2 RATIONALE: Drugs used in chemotherapy, such as amonafide, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of amonafide in treating women who have metastatic breast cancer that has progressed after previous chemotherapy.
NCT00087854 ↗ Study of Individualized Amonafide to Treat Prostate Cancer Completed Xanthus Pharmaceuticals, Inc. Phase 1/Phase 2 The purpose of this study is to assess the safety and efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to individualized doses of Amonafide based on acetylator phenotype information (doses adjusted on individual metabolism).
NCT00273884 ↗ Amonafide in Combination With Cytarabine in Secondary AML Completed Xanthus Pharmaceuticals, Inc. Phase 2 This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.
NCT00715637 ↗ Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study Unknown status Antisoma Research Phase 3 Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML. The purpose of this study is to assess the relative efficacy and safety of amonafide in combination with cytarabine compared to daunorubicin with cytarabine in subjects with documented secondary AML.
NCT01066494 ↗ A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) Unknown status Antisoma Research Phase 2 A phase IIa study to evaluate the pharmacokinetic and efficacy of amonafide L-malate (AS1413) in combination with cytarabine in treating patients with acute myeloid leukemia (AML)
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Amonafide

Condition Name

Condition Name for
Intervention Trials
Acute Myeloid Leukemia 2
Breast Cancer 1
Prostate Cancer 1
Secondary Acute Myeloid Leukemia (Secondary AML, sAML) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Leukemia, Myeloid 3
Leukemia 3
Leukemia, Myeloid, Acute 3
Prostatic Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amonafide

Trials by Country

Trials by Country for
Location Trials
United States 42
Australia 5
Canada 4
Russian Federation 2
Ukraine 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
New York 4
California 3
Pennsylvania 2
South Carolina 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amonafide

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 1
Phase 2 3
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 3
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amonafide

Sponsor Name

Sponsor Name for
Sponsor Trials
Xanthus Pharmaceuticals, Inc. 2
Antisoma Research 2
National Cancer Institute (NCI) 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 4
NIH 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.